JPMorgan Upgrades Novavax On Potential 'Best-In-Class' COVID Vaccine
August 05, 2020 at 09:20 AM EDT
JPMorgan analyst Eric Joseph upgraded Novavax to Overweight from Neutral with a price target of $275, up from $105.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|